LONDON, April 14 -- The government of the United Kingdom issued the following news:
The Medicines and Healthcare products Regulatory Agency (MHRA)has today, 14 April 2026,approvedthe newsingle-dose 7.2mg semaglutide (Wegovy) pen to treat adult patients with obesity, who have a Body Mass Index (BMI) of 30kg/m² or higher.
Today's approval will support adult patients with obesity byprovidingthe option of asingle-doseinjectionto receive themaximumweekly dose for weight loss and weight management.
The 7.2mg dose is administered via one injection.
Patients should always use this medicine exactly as their prescriber tells them and to check with their doctor, pharmacist,or nurse ifthey'renot sure.
This does not apply to overweight patients with a BMI of less than30kg/m² using Wegovyfor weightmanagement or for patients usingWegovyto lower their risk of serious heart problems.
This decision follows theJanuary 2026 authorisation of the 7.2mg maximum weekly dose, whichrequiredthree 2.4mg doses administered on the same day using the standard 2.4mgpen.
When patients start usingWegovy, the starting dose is 0.25mg per week, which will be gradually increased every four weeks asrequiredand prescribed by theappropriate healthcareprofessional. Themaximumdose is 7.2mg per week.
As with any medicine, the MHRA will keep the safety and effectiveness ofWegovyunder close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme, either through thewebsite(https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.
Notes to editors
*
More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on theMHRA Products websitewithin 7 days of approval.
*
For more information on obesity and weight management visit the NHS website
Disclaimer: Curated by HT Syndication.
